Drug prescribing and potential drug-drug interactions at the paediatric unit of a secondary health facility in Southern-Ijaw Local Government Area, Niger Delta Region, Nigeria
Main Article Content
Abstract
Background: Drug interactions resulting from multidrug prescribing can be desirable and/or non-desirable.
Objectives: To assess drug prescribing and potential drug-drug interactions at the paediatric unit of Amassoma General Hospital in the Southern-Ijaw Local Government Area, Bayelsa State, Niger Delta Area of Nigeria.
Methods: Retrospective evaluation of randomly selected 227 case notes of paediatric patients (aged, <12 years), who attended clinics at the study center from January 01 to December 31, 2020 was carried out. Pertinent data collected on diseases, medications prescribed, selected prescribing indicators, and potential drug-drug interactions (pDDIs) identified were presented descriptively, in simple percentages, mean, and median as appropriate. Where necessary, average values were compared using student-t test, and a p-value less than 0.05 was considered statistically significant.
Results: Each of the paediatric patients presented with average of 2.07 ± 0.79 diseases per encounter, and majority (252, 56.2%) were treated for infections. Average of 4.37 ± 1.73 drugs were ordered per encounter, and antiinfectives (423, 42.8%) were the most prescribed. All selected prescribing indicators were not within referenced standards, excluding encounters with injections prescribed (19.2%). A total of 160 (70.5%) of all 227 prescriptions vetted contained at least a pDDI. In all, average of 1.35 ± 1.28 pDDIs were observed per prescription, of which 0.93 ± 0.82 and 0.42 ± 0.77 (p < 0.05) were desirable and non-desirable, respectively. Adverse events (72, 74.2%) and reduction in effectiveness (25, 25.8%) of medication therapy constituted the main potential clinical consequences of non-desirable pDDIs identified.
Conclusion: The paediatric patients seen at the study center routinely present with infections, and were mostly prescribed anti-infective agents. Drug prescribing practice observed was grossly suboptimal and there were several cases of non-desirable pDDIs.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Share
References
World Health Organization (1993). How to investigate drug use in health facilities: selected drug use indicators. Geneva: WHO/DAP/93.1, 1993.
WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology & WHO
Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services (?2003)?. Introduction to drug utilization research. World Health Organization. Available at: https://apps.who.int/iris/handle/10665/42627 (Accessed August 22, 2021).
Cascorbi I (2012). Drug interactions-principles, examples and clinical consequences. Dtsch Arztebl Int 109(33-34): 546-556.
Rafiei H, Abdar ME, Amiri M, Ahmadinejad M (2013). The Study of Harmful and Beneficial Drug Interactions in Intensive Care, Kerman, Iran. J Intensive Care Soc 14(2): 2-5.
Morales-Rios O, Jasso-Gutierrez L, Reyes-Lopez A, Garduno-Espinosa J, Munoz-Hernandez O (2018). Potential drug-drug interactions and their risk factors in pediatric patients admitted to the emergency department of a tertiary care hospital in Mexico. PLoSONE 13 (1): e0190882. https//doi.org/10.1371/journal.pone.0190882
Tom-Revzon C (2006). Drug Interactions. Pediatr Rev 27(8): 315-317.
Ascierto PA, Marincola FM (2011). Combination therapy: the next opportunity and challenge of medicine. J Transl Med 9:115.
Nature Editorial (2017). Rationalizing combination therapies. Nat Med 23(10): 1113.
Isah AO, Laing R, Quick J, Mabadeje AFB, Santoso B, Hogerzeil H, Ross-Degan D (2002). The Development of Reference values for the WHO Health Facility Core Prescribing Indicators. West Afr J Pharm Drug Res 18: 6 - 11.
World Health Organization (2020). International statistical classification of diseases and related health problems (11th ed.). Available at:
WHO Collaborating Centre for Drug Statistics Methodology (2019). Guidelines for ATC classification and DDD assignment 2020. Oslo,Norway, 2019.
Diwakar L, Roberts TE, Cooper NAM, Middleton L, Jowett S, Daniels J, Smith P, Clark TJ; OPT trial collaborative group (2016). An economic evaluation of outpatient versus inpatient polyp treatment for abnormal uterine bleeding. BJOG 123 (4): 625-631.
Statista (2020). Poverty headcount rate in Nigeria as of 2019, by state. Available at: https://www.statista.com/statistics/1121438/pove
rty-headcount-rate-in-nigeria-by-state/ (Accessed May 31, 2021).
Wang J, Zheng X and Chen J (2021). Clinical progression and outcomes of 260 patients with severe COVID-19: an observational study. Sci Rep 11:3166.
Baker C (2017). Accident and Emergency Statistics: Demand, Performance and Pressure. House of Commons Library: Briefing Paper Number 6964.
Vlassoff C (2007). Gender differences in determinants and consequences of health and illness. J health Popul Nutr 25(1): 47-61.
Roser M, Ritchie H (2016). "Burden of Disease". Available at: https://ourworldindata.org/burden-ofdisease (Accessed May 31, 2021).
Bakaki PM, Horace A, Dawson N, Winterstein A, Waldron J, Staley J, Knight EMP, Meropol SBM, Liu R, Johnson H, Golchin N, Feinstein JA, Bolen SD, Kleinman LC (2018). Defining pediatric polypharmacy: A scoping review. Plos ONE 13(11): e0208047. https://doi.org/10.1371/journal.pone.0208047.
Centers for Disease Control and Prevention (2020). Parasites - Children. Source: Global Health, Division of Parasitic Diseases and Malaria. Available at: https://www.cdc.gov/parasites/children.html (Accessed May 30, 2021).
UNICEF (2019). Childhood Diseases. Available at: https://www.unicef.org/health/childhood-diseases (Accessed May 30, 2021).
Fadare J, Olatunya O, Oluwayemi O, Ogundare O (2015). Drug prescribing pattern for under-fives in a paediatric clinic in South-Western Nigeria. Ethiop J Health Sci 25(1): 73-78.
Ivanovska V, Rademaker CMA, van Dijk L, MantelTeeuwisse AK (2014). Pediatric Drug Formulations: A Review of Challenges and Progress. Pediatr 134: 361-372.
Rashed AN, Wong ICK, Wilton L, Tomlin S, Neubert A (2015). Drug Utilisation Patterns in Children Admitted to a Paediatric General Medical Ward in Five Countries. Drugs Real World Outcomes 2(4) :397-410.
Biradar SM, Khaja HBS, Urmila G, Vaishnavi K, Biradar S, Sorangavi V, Marapur SC, Kalyane NV (2019). Assessment of drug utilization patterns in paediatric patients in comparison with WHO core indicators. GSC Biol Pharm Sci 9(2), 84-92.
Madadi P, Enato EFO, Fulga S, Umeoduagu CC, MacLeod SM, Koren G, Einarson TR (2012). Patterns of paediatric analgesic use in Africa: a systematic review. Arch Dis Child 97:1086-1091.
Neubert A, Verhamme K, Murray ML, Picelli G, Hsia Y, Sen FE, Giaquinto C, Ceci A, Sturkenboom M, Wong IC; TEDDY Network of Excellence (2010). The prescribing of analgesics and non-steroidal antiinflammatory drugs in paediatric primary care in the UK, Italy and the Netherlands. Pharmacol Res 62(3): 243-248.
Mesek I, Nellis G, Lass J, Metsvaht T, Varendi H, Visk H, Turner MA, Nunn AJ, Duncan J, Lutsar I (2019). Medicines prescription patterns in European neonatal units. Int J Clin Pharm 41(6):1578-1591.
Jahan S, Al-Saigul A, Hamdelsseed S (2019). Primary health care physicians' prescribing patterns for children under five in Qassim, Saudi Arabia. Prim Health Care Res Dev 20: E 89. doi:10.1017/S1463423619000148.